If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
Description
The monoclonal antibody CML26 recognizes human CML (carboxymethyl-lysine). CML is known to be formed from the oxidation of both carbohydrates and lipids. This makes CML- a biomarker of general oxidative stress. Carboxymethyl-lysine (CML) is a well-characterized glycoxidation product that accumulates in tissues with age, and its rate of accumulation is accelerated in diabetes. Glycoxidation products are a subset of advanced glycation endproducts (AGEs) that are formed by the nonenzymatic glycation and subsequent irreversible oxidation of proteins. Oxidative stress and protein modification have been implicated in the pathogenesis of the chronic complications of diabetes, including nephropathy and atherosclerosis. The accumulation of CML in long-lived tissue such as skin collagen reflects oxidative stress over an extended period of the life-span, and has been shown to be greater in patients with diabetic complications than those without complications.